Ronald van Vollenhoven
Overview
Explore the profile of Ronald van Vollenhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
138
Citations
7766
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Morand E, van Vollenhoven R, Furie R, Kalunian K, Manzi S, Abreu G, et al.
Ann Rheum Dis
. 2025 Feb;
PMID: 39948001
Objectives: To investigate the long-term impact of anifrolumab versus placebo on lupus low disease activity state (LLDAS) and definition of remission in systemic lupus erythematosus (DORIS) attainment in patients with...
2.
Vasileiadis G, Zhang Y, Fatima T, van Vollenhoven R, Lampa J, Gudbjornsson B, et al.
ACR Open Rheumatol
. 2024 Nov;
7(1):e11756.
PMID: 39496558
Objective: The objective of this study was to determine if baseline adiponectin, leptin, and resistin levels are associated with response to antirheumatic treatment in early rheumatoid arthritis (RA). Methods: This...
3.
Werth V, Merrill J, Furie R, Dorner T, van Vollenhoven R, Lipsky P, et al.
J Am Acad Dermatol
. 2024 Oct;
92(3):435-443.
PMID: 39461504
Background: Iberdomide, a cereblon modulator, promotes degradation of transcription factors Ikaros and Aiolos. Objective: Evaluate iberdomide efficacy and safety in cutaneous lupus erythematosus (CLE) in a phase 2 study. Methods:...
4.
Scheffler J, Drevinge C, Lindholm C, Gjertsson I, Lend K, Hetland M, et al.
ACR Open Rheumatol
. 2024 Oct;
7(1):e11742.
PMID: 39411912
Objective: The high prevalence of osteoporosis in rheumatoid arthritis (RA) is due to inflammation that stimulates differentiation of osteoclasts, a process involving circulating monocytes and T cell-derived factors. The aim...
5.
Parodis I, Lindblom J, Levy R, Zen M, Cetrez N, Gomez A, et al.
Lancet Rheumatol
. 2024 Aug;
6(11):e751-e761.
PMID: 39208825
Background: Disease remission or low disease activity are key treatment targets for patients with systemic lupus erythematosus (SLE). Pivotal trials of belimumab were conducted before the introduction of these targets....
6.
Aranow C, Allaart C, Amoura Z, Bruce I, Cagnoli P, Chatham W, et al.
Ann Rheum Dis
. 2024 Aug;
83(11):1502-1512.
PMID: 39159997
Objectives: Disease activity control in patients with systemic lupus erythematosus (SLE) with corticosteroid and immunosuppressant withdrawal is a treatment goal. We evaluated whether this could be attained with sequential subcutaneous...
7.
van Vollenhoven R, Strand V, Takeuchi T, Chavez N, Walter P, Singhal A, et al.
Arthritis Res Ther
. 2024 Jul;
26(1):143.
PMID: 39075620
Background: To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the...
8.
Askanase A, Furie R, DallEra M, Bomback A, Schwarting A, Zhao M, et al.
Lupus Sci Med
. 2024 May;
11(1).
PMID: 38777595
Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was 'minimising disease activity with the fewest treatment-associated toxicities and slowing or preventing organ damage progression'. The...
9.
Liu J, Idborg H, Korotkova M, Lend K, van Vollenhoven R, Lampa J, et al.
Arthritis Res Ther
. 2024 Mar;
26(1):61.
PMID: 38444034
Background: Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient's response to these therapies. Prostanoids, encompassing prostaglandins,...
10.
Piga M, Chessa E, Morand E, Ugarte-Gil M, Tektonidou M, van Vollenhoven R, et al.
Lancet Rheumatol
. 2024 Jan;
4(6):e441-e449.
PMID: 38293958
The Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus (PISCOS) study aimed to obtain an evidence-based and expert-based consensus standardisation of the Physician Global Assessment (PGA) scoring of...